Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Spero Therapeutics Inc (SPRO) USD0.001

Sell:$10.72 Buy:$10.74 Change: $0.61 (5.37%)
NASDAQ:0.83%
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$10.72
Buy:$10.74
Change: $0.61 (5.37%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$10.72
Buy:$10.74
Change: $0.61 (5.37%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720. SPR994 is novel oral formulation of tebipenem, a carbapenem-class antibiotic. SPR994 is effective against a broad spectrum of MDR bacterial infections, its initial focus is on the treatment of cUTIs. Potentiator platform that enables to develop drugs that expand the spectrum and potency of existing antibiotics, including inactive antibiotics, against Gram-negative bacteria. SPR720 is novel oral therapy product candidate designed for the treatment of NTM, a rare lung infection often occurring in patients with compromised immune systems, including HIV, or respiratory conditions, such as cystic fibrosis, asthma and bronchiectasis.

Contact details

Address:
675 Massachusetts Ave Ste 14
CAMBRIDGE
02139-3309
United States
Telephone:
+1 (857) 2421600
Website:
https://sperotherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SPRO
ISIN:
US84833T1034
Market cap:
$201.86 million
Shares in issue:
18.66 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Milind Deshpande
    Independent Chairman of the Board
  • Ankit Mahadevia
    President, Chief Executive Officer, Director
  • Cristina Larkin
    Chief Operating Officer and Chief Commercial Officer
  • Timothy Keutzer
    Senior Vice President - Development
  • Thomas Parr
    Chief Scientific Officer
  • David Melnick
    Cheif Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.